CClinicalTrials.gg
CompletedNCT00636363Updated Mar 24, 2015Results posted

Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution

An interventional study of Bausch & Lomb Multipurpose Solution - Rub Care and Bausch & Lomb Multipurpose Solution - No Rub Care in Contact Lens Solutions, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-24.

Sponsored by Bausch & Lomb Incorporated · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To the safety and efficacy of a Bausch \& Lomb Multipurpose Solution when compared to Ciba vision Aquify Multipurpose solution

02

Conditions studied

  • Contact Lens Solutions
03

In context

Lead sponsor

Bausch & Lomb Incorporated is the lead sponsor of 219 studies on the registry; 7 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 41 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • subject is a habitual wearer of a silicone hydrogel or group IV contact lens
  • VA correctable to 0.3 LogMar or better (driving vision)
  • Clear central cornea
  • Subject uses a lens care system on a regular basis

Exclusion criteria

Exclusion Criteria:

  • Systemic disease affecting ocular health
  • Using systemic or topical medications
  • wear monovision, multifocal or toric contact lenses
  • Any grade 2 or greater slit lamp findings
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    Multipurpose Solution - Rub Care

    Bausch \& Lomb Multipurpose Solution for use with contact lens care

    Device: Bausch & Lomb Multipurpose Solution - Rub Care

  • Experimental
    Multipurpose Solution - No Rub Care

    Bausch \& Lomb Multipurpose Solution for use with contact lens care

    Device: Bausch & Lomb Multipurpose Solution - No Rub Care

  • Active comparator
    Ciba Vision Aquify Multipurpose Solution

    Ciba Vision Aquify Multipurpose Solution for use with contact lens care

    Device: Ciba Vision Aquify Multipurpose Solution

Interventions

  • DeviceBausch & Lomb Multipurpose Solution - Rub Care

    Daily care for contact lenses - rub care regimen

  • DeviceBausch & Lomb Multipurpose Solution - No Rub Care

    Daily care for contact lenses - no rub care regimen

  • DeviceCiba Vision Aquify Multipurpose Solution

    daily care for contact lenses

06

What researchers measure

Primary outcomes

  1. Slit-lamp Findings > Grade 2

    eyes with any slit lamp findings greater than Grade 2 at any visit. Slit lamp findings for each eye will be graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). Epithelial edema, epithelial microcysts, corneal staining, limbal injection, bulbar injection, superior tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be assessed.

    Time frame: Over 4 visits for 3 month period

  2. Subjective Responses to Comfort Related Symptoms/Complaints

    Subject symptoms/complaints will be assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.

    Time frame: Over 4 visits for the 3 month period

  3. Contact Lens Deposits

    Lens deposits assessed at each follow-up visit. Degree of deposits assessed as none, light, medium, or heavy.

    Time frame: At each visit for 3 months

07

Results

Posted Apr 8, 2011

Participant flow

541 participants were enrolled in this 3 month study (1152 eyes). First participant was enrolled Mar 7, 2008 and last participant exited Aug 1, 2008. Participant were enrolled from 24 investigative sites in the US.

Participant flow — Overall Study
MilestoneMultipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose Solution
Started178176181
Completed165156163
Not completed132018
Withdrew: Conjunctivitis001
Withdrew: Adverse event001
Withdrew: Positive slit lamp finding021
Withdrew: Study related symptoms/complaints874
Withdrew: Met ineligibility criteria003
Withdrew: Missed > 1 visit013
Withdrew: Lack of motivation101
Withdrew: Protocol violation030
Withdrew: Lost to follow-up342
Withdrew: Withdrawal by subject132

Outcome measures

PrimarySlit-lamp Findings > Grade 2

eyes with any slit lamp findings greater than Grade 2 at any visit. Slit lamp findings for each eye will be graded for severity on a scale from 0 (No Finding) to 4 (Severe Finding). Epithelial edema, epithelial microcysts, corneal staining, limbal injection, bulbar injection, superior tarsal conjunctival abnormalities, corneal neovascularization, and corneal infiltrates will be assessed.

Time frame:
Over 4 visits for 3 month period
Reported as:
Number · participants
Slit-lamp Findings > Grade 2
participantsMultipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose Solution
Slit-lamp Findings > Grade 2343
PrimarySubjective Responses to Comfort Related Symptoms/Complaints

Subject symptoms/complaints will be assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.

Time frame:
Over 4 visits for the 3 month period
Reported as:
Mean · Scores on a Scale
Subjective Responses to Comfort Related Symptoms/Complaints
Scores on a ScaleMultipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose Solution
Comfort88.7 ± 12.984.6 ± 16.586.9 ± 13.9
End of day comfort83.2 ± 17.677.1 ± 20.879.1 ± 18.6
Burning/stinging upon inserstion91.1 ± 13.589.1 ± 15.890.1 ± 15.9
Irritation88.7 ± 15.385.0 ± 17.486.8 ± 15.2
Itching91.6 ± 12.790.9 ± 12.990.8 ± 14.1
Dryness88.2 ± 14.083.0 ± 19.083.7 ± 16.4
Redness91.4 ± 13.291.0 ± 13.191.2 ± 14.0
Vision91.9 ± 10.988.9 ± 16.292.6 ± 10.9
Lens cleanliness92.2 ± 11.789.2 ± 15.391.8 ± 10.8
Lens Handling95.1 ± 9.095.1 ± 7.294.9 ± 8.5
PrimaryContact Lens Deposits

Lens deposits assessed at each follow-up visit. Degree of deposits assessed as none, light, medium, or heavy.

Time frame:
At each visit for 3 months
Reported as:
Number · Eyes
Contact Lens Deposits
EyesMultipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose Solution
None985291
Light147176178
Medium848469
Heavy212612

Adverse events

Collected over 3 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Multipurpose Solution - Rub Care—0/178 (0%)0/178 (0%)
Multipurpose Solution - No Rub Care—0/176 (0%)0/176 (0%)
Ciba Vision Aquify Multipurpose Solution—0/181 (0%)0/181 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Multipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose SolutionTotal
18-66 years of age178176181535
Sex: Female, Male
Sex: Female, Male(Participants)Multipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose SolutionTotal
Female124133126383
Male544355152
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Multipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose SolutionTotal
Hispanic or Latino104721
Not Hispanic or Latino168172174514
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Multipurpose Solution - Rub CareMultipurpose Solution - No Rub CareCiba Vision Aquify Multipurpose SolutionTotal
United States178176181535
08

Study locations

1 site
  • Place Eye Care
    LeRoy, New York 14482, United States
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00636363
Lead sponsor
Bausch & Lomb Incorporated
Responsible party
Sponsor
First posted
Mar 14, 2008
Start date
Mar 2008
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Apr 8, 2011
Last update
Mar 24, 2015

Study contacts

Mohinder Merchea, OD, PhD
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion